首页>投融资
Wave Life Sciences
增发
Wave Life Sciences Ltd.于2012年7月23日在新加坡注册成立。该公司是一家临床生物制药公司,以创新和专有合成化学药物开发平台,使用的设计,开发和商业化的先入类或最佳的类核酸治疗考生广泛的管道。核酸治疗有解决那些难以治疗与小分子药物和生物制剂的潜力,并已成为一个庞大而有前途的一类药物。公司最初开发核酸治疗剂靶向的遗传缺陷要么减少疾病促进蛋白质的表达或改造生产失调突变蛋白进入生产的功能性蛋白质。该公司的平台是由其创新和专有立体技术的推动,使之合理设计,优化和制造stereopure核酸治疗,它认为具有药物属性优于寡核苷酸的立体异构体混合物,目前市场上还是处在发展中。
基本信息
-
公司全称Wave Life Sciences Ltd
-
类型遗传药物研发商
-
产业领域药品研发/制造、医药研发/制造、生物药、化学药
-
公司人数101~500人
-
地址7 Straits View #12-00 Marina One East Tower Singapore
-
联系电话65-6-2363388
-
邮箱info@wavelifesci.com
-
成立时间2012-01-01
投融资
-
2024-10-01增发2.3亿美元未透露
-
2024-09-27增发2亿美元未透露
-
2020-09-23增发1亿美元未透露
-
2015-12-14上市后再融资3000万美元Teva Pharmaceutical Industries
-
2015-11-11上市9486.0万美元未透露
-
2015-08-18B轮6600万美元RA Capital鱼鹰资管Redmile GroupJennison Associates富达国际Foresite CapitalNLVP
-
2015-02-02A轮1800万美元RA CapitalKagoshima Shinsangyo Sosei Investment LPShin Nippon Biomedical Laboratories
- 加载更多
相关投融资企业
收并购
Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, founded in 2002 by Italian academics as a spin-off from the European Organization for Nuclear Research (CERN, Switzerland), develops diagnostic and therapeutic products, including PET radiopharmaceuticals. The company focuses on Personalized Medicine, aimed at providing treatments tailored to a patient's profile and disease, using predictive, preventive and personalized procedures. In January 2018, AAA became a subsidiary of Novartis AG.In July 2016, the company opened its first US manufacturing facility in Millburn, NJ. The Millburn plant served as a distribution center for NETSPOT.In April 2014, AAA opened a new office in the US located at Manhattan, NY. At that time, the company planned to set up a new manufacturing facility in the US.In February 2012, AAA planned to build a radiopharmaceutical facility in Murcia, Spain. The facility was expected to be completed within 18 months.By December 201
B轮
Veradermics Inc (美国):Veradermics是一家位于美国的生物技术公司,专注于皮肤健康和美容产品的研发。公司的主要研究领域包括皮肤再生、抗衰老和皮肤修复。Veradermics利用其专有的生物材料和技术平台,开发了一系列高效的皮肤护理产品。公司的产品线包括抗衰老面霜、皮肤修复凝胶和皮肤再生面膜等。
B轮
Qnovia, formerly known as Respira Technologies, is focused on developing inhaled drug delivery platforms to deliver drugs for nicotine replacement therapy and cardiopulmonary diseases.In September 2022, the company changed its name from Respira Technologies to Qnovia.In September 2022, the company raised USD 17M in Series A funding led by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures,